> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Lifts 2026 Product Sales Outlook To $31.0 Billion-$31.3 Billion, But Still Guides To A Loss
- URL: https://www.bullished.co/gilead-lifts-2026-product-sales-outlook-to-31-0-billion-31-3-billion-but-still-guides-to-a-b94bb510/
- Published: 2026-10-29T21:33:16.000Z
- Updated: 2026-10-29T21:33:16.000Z
- Description: HIV sales rose 18% in the third quarter, yet $12.4 billion in acquired research charges widen the projected full-year loss per share.
- Author: Matteo Parrino
- Tags: Deals, GILD, Industry: Healthcare

Gilead Sciences, the biopharmaceutical company behind HIV, liver disease and cancer drugs, raised its 2026 product sales forecast to [$31.0 billion to $31.3 billion](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000037/exhibit991earningspressrel.htm?ref=bullished.co), from $30.1 billion to $30.4 billion in August, as third-quarter HIV sales climbed 18%. The company said Thursday in an [8-K filing](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000037/gild-20261029.htm?ref=bullished.co) that it still expects a full-year loss per share.

## HIV carries the quarter

Third-quarter product sales rose 13% to [$8.3 billion](https://markets.ft.com/data/announce/detail?dockey=600-202610291602BIZWIRE%5FUSPRX%5F%5F%5F%5F20261029%5FBW068948-1&ref=bullished.co). HIV sales rose 18% to $6.2 billion, helped by higher realized prices, stronger prevention demand and favorable inventory dynamics, the company said.

Biktarvy, the top seller, grew 10% to [$4.1 billion](https://markets.ft.com/data/announce/detail?dockey=600-202610291602BIZWIRE%5FUSPRX%5F%5F%5F%5F20261029%5FBW068948-1&ref=bullished.co). Descovy rose 49% to $1.0 billion, and Trodelvy, a breast cancer drug, rose 42% to $506 million.

Veklury, the COVID-19 drug, fell 69% to $86 million on fewer COVID-related hospitalizations. Cell therapy sales fell 18% to $355 million, which the company attributed to ongoing competitive headwinds.

CEO Daniel O'Day called it "an exceptional third quarter," and said the base business guidance increase totals $1.6 billion since the start of 2026.

## Profit slips, loss guidance widens

Diluted earnings per share fell to $1.94 from $2.43 a year earlier, mainly because equity securities swung to losses from gains. Adjusted earnings per share rose to $2.55 from $2.47.

For the full year, Gilead now expects a diluted loss of $4.05 to $4.40 per share, against $3.40 to $3.75 in August. The adjusted loss is guided at $0.85 to $1.20, versus $0.30 to $0.65 before.

The guidance includes about $9.88 per share from $12.4 billion of acquired research charges tied to the Arcellx, Tubulis, Ouro Medicines and PepStar deals, net of the Lakefront collaboration and related taxes. Acquired research expenses for the first nine months were $11.3 billion.

## Cash drawn down by dealmaking

Cash and marketable securities stood at $6.4 billion on September 30, down from $10.6 billion at the end of 2025\. Acquisitions took $11.3 billion this year, with $2.8 billion in debt repayments, $3.1 billion in dividends and $1.1 billion in buybacks, offset by $11.2 billion of operating cash flow and $4.1 billion of net debt proceeds.

Third-quarter operating cash flow was $5.0 billion. The Medicare-negotiated maximum price for Biktarvy will affect revenue starting January 1, 2028, the company said.

The board declared a $0.82 quarterly dividend, payable December 30 to holders of record on December 15\. The PepStar deal, for an oral IL-23R inhibitor program, is still awaiting closing conditions.

Gilead's $0.82 dividend goes to holders of record on December 15 and is payable December 30.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — GILEAD SCIENCES, INC. (GILD)](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000037/gild-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991earningspressrel.htm — GILEAD SCIENCES, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000882095/000088209526000037/exhibit991earningspressrel.htm?ref=bullished.co) — SEC EDGAR
- [Gilead Sciences Announces Third Quarter 2026 Financial Results – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610291602BIZWIRE%5FUSPRX%5F%5F%5F%5F20261029%5FBW068948-1&ref=bullished.co) — Financial Times